XOMA · Categories · Earnings
XOMA - Earnings announcements
XOMA Royalty Corporation (XOMA) earnings announcements - real-time wire coverage filtered to Earnings only.
Recent Earnings for XOMA
- Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty AggregatorTransaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.501 and expects the transaction to be accretive by $1.50 per share to adjusted EPS in 20272 Ligand to hold investor call at 8:00 a.m. ET today JUPITER, Fla. and EMERYVILLE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporate
- XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026EMERYVILLE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty announced today it will report fourth quarter and full year 2025 financial results on Wednesday, March 18. The Company will host a webcast on March 18, 2026, at 8:00 am Eastern Time to discuss the results and provide a business update. The webcast will be accessible on the "News & Events" page in the Investors section of XOMA Royalty's website (www.investors.xoma.com/news-events). A replay of the webcast will be available for 30 days following the live event. About XOMA Royalty CorporationXOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in he